Methodology

New confirmed deaths reported in the last 7 days per 100,000 population

Sources: WHO Coronavirus (COVID-19) Dashboard

Cumulative number of persons fully vaccinated with the last recommended dose per 100 population

Sources: WHO Coronavirus (COVID-19) Dashboard

Cumulative number of persons vaccinated with at least one dose per 100 population

Sources: WHO Coronavirus (COVID-19) Dashboard

1. # of countries not on track to reach 40% coverage by End Dec 2021 (see later);
2. # of doses (Mn) needed for all countries to reach 40% based on a) administered, b) shipped and c) secured supply a. Total number of additional vaccine courses needing to be administered in order to vaccinate 40% of total population wastage b. Total number of additional vaccine courses needing to be received in-country in order to vaccinate 40% of total population, including a standard assumption of 10% wastage c. Total number of additional vaccine courses needing to be secured in order to vaccinate 40% of total population, including a standard assumption of 10% wastage

Sources: WHO CRD

1. # of countries not on track to reach 70% coverage by mid-2022 (see later)

2. # of doses (Mn) needed for all countries to reach 70% based on a) administered, b) shipped and c) secured supply a. Total number of additional vaccine courses needing to be administered in order to vaccinate 70% of total population wastage b. Total number of additional vaccine courses needing to be received in-country in order to vaccinate 70% of total population, including a standard assumption of 10% wastage c. Total number of additional vaccine courses needing to be secured in order to vaccinate 70% of total population, including a standard assumption of 10% wastage

Sources: WHO CRD

Secured and/or Expected Vaccine Supply (% of total population)

This includes coverage from bilateral contracts, regional deals, COVAX, in-kind donation, domestic production, and contracts supported by MDB financing. Some contracts are unobserved which may lead to under-reporting of coverage in some countries. Optional contract and unallocated AVAT doses are excluded to remain conservative.

Sources: IMF-WHO COVID-10 Vaccine Supply Tracker

Expected Effective Vaccine Supply by End Dec (% of Population)

Effective vaccine supply is defined as total expected doses divided by 2 per population. J&J and CanSino volumes have been doubled for comparability with the other two dose candidates in the portfolio.

Sources: IMF-WHO COVID-19 Vaccine Supply Forecast Dashboard

Exports are defined as the number of doses delivered across borders from producing economies to economies where vaccines are administered. The graph displays:

1. Cumulative exports by country producing economies over time
2. Monthly export by country producing economies over time

A "producing economy" is defined as a country or territory where final vaccines are made or where "fill and finish" is completed. This definition does not consider exports of vaccine substances in bulk form shipped to "fill and finish" sites located in other countries or territories.

Sources: WTO-IMF Vaccine Trade Tracker

Projected demand, purchases, supply forecast, allocation, delivery, and financing gaps for vaccine doses by ACT-A

Sources: COVAX supply forecast / UNICEF COVAX Procurement Portal / ACT-A Commitment Tracker

Total number of COVID-19 vaccine doses yet to be received as a percentage of total number of COVID-19 vaccine doses secured

Sources: UNICEF Vaccine Market Dashboard / IMF-WHO COVID-10 Vaccine Supply Tracker

Coming soon.

Coming soon.

The absorption capacity levels are calculated based on two indicators, i. Percentage of doses used versus received, i.e. of the doses they have received to-date, which % has been used ii. 4-week daily average vaccination rate as a % of population per day, i.e. on average over the past 4 weeks which % has been vaccinated on a daily basis To determine the levels, different thresholds have been determined based on in-depth analysis of country performance.

In essence, when less than 50% of the doses they have received are used and the average vaccination pace is low, this indicates that absorption is problematic, i.e. they have doses but are not using it.

Sources: WHO CRD Population coverage dataset, COVAX CRD COVID-19 Vaccination rate dataset

Status of progress towards the WHO Strategy to Achieve Global COVID-19 Vaccination by mid-2022, as published on October 6, 2021.

The strategy outlines the urgent actions required by the global community to vaccinate 70% of the world’s population against COVID-19 by mid-2022 including interim targets of 10% full vaccination population coverage in all countries by the end-September 2021, and 40% in all countries by end-2021, as to first protect health workers, older populations, and high-risk individuals with important co-morbidities, advancing next to all adults, followed by adolescents. We display the status population coverage in terms of fully vaccinated people against each of the three targets: a. 10% by end of September 2021: Three categories are being tracked: 1) Goal met by deadline, 2) Goal met after deadline, 3) Goal not yet met b. 40% by end of December 2021: Three categories are being tracked: 1) Goal met by deadline, 2) Goal met after deadline, 3) Goal not yet met c. 70% by end of June 2022: Three categories are being tracker: 1) Goal met, 2) On track, 3) Off track

On track / off track is assigned by first calculating the projected population coverage by deadline by multiplying the 4-week rolling average daily rate of change in number of persons fully vaccinated by the number of days remaining until target deadline. If the percent population coverage by deadline is greater than the target, the country is assigned as on track. If the percent population coverage by deadline is less than the target, the country is assigned as off track.

Sources: WHO CRD

Status of progress against country coverage target by target deadline: 1) Goal met, 2) On track, 3) Off track, 4) No timeline set, 5) No target captured

Tooltip displays days until country coverage target achievement at current rolling 4-week average daily rate, which is calculated by subtracting current actual population coverage from the coverage target, then by dividing this additional population coverage to the be achieved by the 4-week rolling average daily rate of change in number of persons fully vaccinated.

Sources: WHO CRD, Partners Platform

National Deployment & Vaccination Plan in place (and shared with Partners Platform)

Sources: Partners Platform

% of individuals who would get vaccinated once a vaccine is available and recommended

Sources: Risk Communication Community Engagement (RCCE) Collective Service COVID-19 Behavioural Indicators

New confirmed cases reported in the last 7 days per 100,000 population

Sources: WHO Coronavirus (COVID-19) Dashboard

Rolling 7days average of # of tests conducted per 100K population

Sources: FIND Test Tracker

7 day rolling average of % tests with positive outcome

Positivity rate is one of the metrics used to monitor the spread of infection. It signifies the percentage of people testing positive for COVID-19 relative to the number of people tested. It is often suggested that positivity rates under 5% imply that the majority of cases are being identified. Positivity rate can help distinguish between increased testing and increased transmission. Positivity and testing rates together can indicate the testing capacity of each country when there is an active wave of infection.

Sources: FIND Test Tracker

Testing score combines positivity and testing rates together and can indicate the testing capacity of each country when there is an active wave of infection.

Tracking the average testing rates vs average positivity rate in the last 12 months, countries can be grouped in 4 tiers (using median average testing rates and median average positivity rate as thresholds).

We gain insights on country preparedness, relative testing usage and their association with positivity rate, as well as cases and death rates. Higher testing rates (more than 1 per 1000 people per day) correlate with lower positivity rates and lower case rates.

Sources: FIND Test Tracker

% positive tests sequenced and shared via GISAID over last 90 days

Sources: GISAID Submission Tracker

Projected demand, purchases, delivery, and financing gaps for diagnostics by ACT-A

Sources: UN COVID-19 Supply Chain System (CSCS) / ACT-A Commitment Tracker

# of daily tests (per 100K) needed to fill gap between average daily tests for COVID-19 in past 7 days and indicative target of 100/100K/day

Sources: FIND Test Tracker

The ratio of rapid diagnostic tests to PCR tests in use

A combination of different test types is needed to facilitate patient management and public health planning for effective control of COVID-19. Tests that directly detect the virus (PCR or antigen) should be prioritized for diagnosis and monitoring. Controlling COVID-19 requires testing services to be scaled up and access to testing improved in decentralized settings. The limited coverage of laboratory services and long turnaround times mean that capacity for molecular testing assays has been insufficient to meet demand in many countries, particularly in Low- and Middle-income countries.

The disaggregation of reported COVID-19 tests by assay type allows us to gain ingsights on consumption of procured tests, gauge success rates on the implementation of diagnostic tools, foresee demand and prioritize capacity strengthening. Countries should be supported in their effort to make real-time data available, to have systems in place that can provide prognostics on epidemic markers and avoid delayed reaction times.

Sources: FIND Test Tracker

average # of days per month that a country is reporting COVID-19 tests

Sources: FIND Test Tracker

% of hospitals that conduct PCR or RDT tests onsite

Sources: COVID-19 case management capacities: diagnostics, therapeutics, vaccine readiness, and other health products – facility assessment tool

Scores a country's sequencing capability, where

1 = No or unknown SARS-CoV-2 sequencing capacity

2 = SARS-CoV-2 sequencing capacity available at 1-3 facilities

3 = SARS-CoV-2 sequencing capacity at 4 or more facilities

Sources: WHO

Ratio between confirmed deaths and confirmed cases

Sources: Our World In Data

% severe cases treated with adequate Tx depending on severity

Sources: UNITAID M&E, Global COVID-19 Clinical Data Platform

% non-severe cases treated with adequate Tx depending on severity

Sources: UNITAID M&E, Global COVID-19 Clinical Data Platform

Weekly # of new admissions in ICU per million people

Sources: Our World In Data

Projected demand, purchases, delivery, and financing gaps for therapeutics by ACT-A

Sources: UN COVID-19 Supply Chain System (CSCS) / ACT-A Commitment Tracker

% of hospitals with tracer medicine item currently available: Dexamethasone (injectable)/ corticosteroids

Sources: COVID-19 case management capacities: diagnostics, therapeutics, vaccine readiness, and other health products – facility assessment tool

% of hospitals that provide ICU services

Sources: COVID-19 case management capacities: diagnostics, therapeutics, vaccine readiness, and other health products – facility assessment tool

Daily new COVID-19 HCW cases (per 100K pop)

Sources: WHO surveillance data

Daily new COVID-19 HCW cases (per 100K pop)

Sources: WHO surveillance data

The number of deaths from all causes during a crisis above and beyond what we would have expected to see under 'normal' conditions, i.e. compared to a projection based on previous years

Sources: Our World In Data

Level of facilities with IPC/PPE guidelines, PPE available to all staff & COVID-19 safe measures in place

Sources: WHO

% essential health services disrupted due to COVID-19, where service is available

Sources: National pulse survey on continuity of essential health services during the COVID-19 pandemic (Round 2 January - March 2021)

Projected demand, purchases, delivery, and financing gaps for PPE by ACT-A

Sources: UN COVID-19 Supply Chain System (CSCS) / ACT-A Commitment Tracker

% of hospitals with all six IPC/PPE guidelines

Sources: COVID-19 case management capacities: diagnostics, therapeutics, vaccine readiness, and other health products – facility assessment tool

% of hospitals with all six PPE tracer items available for all staff

Sources: COVID-19 case management capacities: diagnostics, therapeutics, vaccine readiness, and other health products – facility assessment tool

% of hospitals that have implemented any measure to create COVID-19 safe environment

Sources: COVID-19 case management capacities: diagnostics, therapeutics, vaccine readiness, and other health products – facility assessment tool